TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04449419

Intervention type: OTHER
Intervention: There is not intervention.
Description: There is not intervention

Intervention type: OTHER
Intervention: There is not intervention.
Description: There is not intervention

Intervention type: OTHER
Intervention: There is not intervention.
Description: There is not intervention

Intervention type: OTHER
Intervention: There is not intervention.
Description: There is not intervention

Intervention type: OTHER
Intervention: There is not intervention.
Description: There is not intervention

Intervention type: OTHER
Intervention: There is not intervention.
Description: There is not intervention
Study: NCT00507936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-894
Description: ABT-894 1 mg capsule BID throughout treatment period
Study: NCT02850289

Intervention type: DRUG
Intervention: Pegylated interferon (PEG-INF) alfa-2a
Description: Pegylated interferon (PEG-IFN) alfa-2a will be administered as per investigator's discretion and will be in line with the current product monograph.
Study: NCT00507936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-894
Description: ABT-894 2 mg capsule BID throughout treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-894
Description: ABT-894 4 mg capsule BID throughout treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule BID throughout the treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine 60 mg QD throughout treatment period
Study: NCT06397430

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: parenteral nutrition supplements
Description: parenteral nutrition

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: enteral nutrition supplements
Description: enteral nutrition

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mixed nutrition supplements
Description: mixed nutrition
Study: NCT02480738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training Apparatus
Description: CoCoTA was developed through collaborative research with the Korean Institute of Science and Technology (KIST) and Primpo Co. Ltd. (www.primpo.com). It was designed to stimulate numerous cognitive domains simultaneously by using sounds and objects familiar to Korean elderly. Training themes and scenarios were developed and evaluated by six board-certified neurologists and three neuropsychologists who specialize in dementia.~Each subject participated in a total of 24 sessions of cognitive training, which consisted of 40 minutes of training, twice per week. To assure the consistency of cognitive training, trained personnel stayed nearby the subjects to help throughout the training process.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Cognitive Training Apparatus
Description: CoCoTA was developed through collaborative research with the Korean Institute of Science and Technology (KIST) and Primpo Co. Ltd. (www.primpo.com). It was designed to stimulate numerous cognitive domains simultaneously by using sounds and objects familiar to Korean elderly. Training themes and scenarios were developed and evaluated by six board-certified neurologists and three neuropsychologists who specialize in dementia.~Each subject participated in a total of 24 sessions of cognitive training, which consisted of 40 minutes of training, twice per week. To assure the consistency of cognitive training, trained personnel stayed nearby the subjects to help throughout the training process.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training Apparatus
Description: CoCoTA was developed through collaborative research with the Korean Institute of Science and Technology (KIST) and Primpo Co. Ltd. (www.primpo.com). It was designed to stimulate numerous cognitive domains simultaneously by using sounds and objects familiar to Korean elderly. Training themes and scenarios were developed and evaluated by six board-certified neurologists and three neuropsychologists who specialize in dementia.~Each subject participated in a total of 24 sessions of cognitive training, which consisted of 40 minutes of training, twice per week. To assure the consistency of cognitive training, trained personnel stayed nearby the subjects to help throughout the training process.
Study: NCT02850289

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin will be administered as per investigator's discretion and will be in line with the current product monograph.
Study: NCT03553108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Treatment A
Description: Olaparib Tablet 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Treatment A
Description: Olaparib Tablet 25 mg
Study: NCT02937623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dissolvable polymer strip containing Novamin (calcium sodium phosphosilicate)
Description: Experimental dissolvable polymer strip containing Novamin (15% weight by weight\[w/w\] calcium sodium phosphosilicate).
Study: NCT01056393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibalizumab 800mg Q2Weeks
Description: Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 800mg every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibalizumab 2000mg Q4Weeks
Description: Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 2000mg every 4 weeks.
Study: NCT03368313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Circaid
Description: Circaid is a velcro compression device for the calf (Circaid Juxtalite® Lower Leg; Medi Gmbh, Bayreuth, Germany), thigh and knee (Circaid Juxtafit; Medi Gmbh, Bayreuth, Germany). The Circaid device will be applied with an average pressure of more than 40 mmHg, verified through a BPS (built-in pressure system).
Study: NCT01493245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNS020QD
Description: During weeks 1-3, initial doses of 0.84 mg, 1.7 mg, 3.4 mg, or 5 mg can be increased until individual optimal dose (up to maximum 20.1 mg) is determined. The optimal dose will be administered during the maintenance period (1 week), followed by a long-term treatment (48 weeks) period, where the dose will be adjusted (escalated or reduced) in consideration of the efficacy of the study, and the condition of adverse events. The patches are applied on the skin and exchanged daily (every 24 hours) for consecutive 52 weeks.
Study: NCT03553108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Treatment A
Description: Olaparib Tablet 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Treatment A
Description: Olaparib Tablet 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Treatment B
Description: Olaparib Tablet 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Treatment B
Description: Olaparib Tablet 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Treatment B
Description: Olaparib Tablet 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Treatment B
Description: Olaparib Tablet 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Treatment C
Description: Olaparib Tablet 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Treatment C
Description: Olaparib Tablet 150 mg
Study: NCT02199769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: Investigators will develop and implement an automated Diabetes Detection Tool (DDT) that does data mining on EMR lab data to systematically identify all primary care patients with elevated RPGs who are at high risk of diabetes and in need of further diabetes testing/screening.
Study: NCT04328337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid, 20% Intravenous Emulsion
Description: Infusion of Intralipid 20%
Study: NCT03553108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Treatment C
Description: Olaparib Tablet 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Treatment C
Description: Olaparib Tablet 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Treatment D
Description: Olaparib Tablet 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Treatment D
Description: Olaparib Tablet 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Treatment D
Description: Olaparib Tablet 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Treatment D
Description: Olaparib Tablet 250 mg
Study: NCT04328337

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: saline 30 ml/hr for 12 hours through an IV
Study: NCT01872559

Intervention type: OTHER
Intervention: 3D Sonography analysis
Description: Those patients who are scheduled to have an ultrasound as part of their infertility treatment will be offered the opportunity to have additional measurements done at the time of their ultrasound; these additional measurements will take less than 2 minutes and do not require any additional sonograms, tests, or interventions.
Study: NCT00632489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib, 1000 mg PO daily will be added to this combination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib, 1000 mg PO daily will be added to this combination.
Study: NCT05010343

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: carbon ion irradation
Description: All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Ion Irradiation With SIB
Description: All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle, and with simultaneous integrated boost (SIB) to the gross tumor in the PSMA PET/CT and mpMRI
Study: NCT03545477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel locomotion treatment: curved-walking training
Description: Each training session is comprehensive of a 30-minute walking training on curved trajectory (S trajectory composed by two semicircle with a radius of 1.2 m)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard locomotion treatment: straight-walking training
Description: It consists of 30 minutes of locomotion training on straight trajectories, as typically proposed during traditional gait rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physical therapy
Description: It consists of 60 minutes of stretching, muscular conditioning and coordination,postural exercises for trunk control, standing, functional exercies and upper limb rehabilitation, customized on patient's need.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: It consists of 60 minutes of stretching, muscular conditioning and coordination,postural exercises for trunk control, standing, functional exercies and upper limb rehabilitation, customized on patient's need.
Study: NCT03984084

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04348253

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Berger
Description: Treatment 1

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3LT
Description: Treatment 2
Study: NCT03297424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX2853
Description: tablets
Study: NCT03478904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide Liquid
Description: Enzalutamide liquid formulation given orally (160mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide Liquid
Description: Enzalutamide liquid formulation given orally (160mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide Capsule
Description: Enzalutamide gel capsule (4X 40mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide Capsule
Description: Enzalutamide gel capsule (4X 40mg)
Study: NCT00880204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESS-EMCH training
Description: The trainings of the ESS-EMCH programme are based on two well-tried and tested structured training methodologies of Advanced Pediatric Life Support (APLS) and Management of Obstetric Emergencies and Trauma (MOET).
Study: NCT02304692

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Bone anchored hearing aid

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone anchored hearing aid
Study: NCT01955408

Intervention type: OTHER
Intervention: Questionnaires, anticholinergic treatment, urodynamic study
Study: NCT00647933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 36286
Description: Subcutaneous Org 36286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 36286
Description: Subcutaneous Org 36286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 36286
Description: Subcutaneous Org 36286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 36286
Description: Subcutaneous Org 36286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyndiol®
Description: Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) tablets orally once a day for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyndiol®
Description: Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) tablets orally once a day for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyndiol®
Description: Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) tablets orally once a day for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyndiol®
Description: Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) tablets orally once a day for 6 weeks.
Study: NCT00311389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution
Description: Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005%/Timolol 0.005% ophthalmic solution
Description: Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
Study: NCT00878683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: silicone catheter boot
Description: silicone device using Dermabond
Study: NCT01594775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon (Oxytocin) nasal spray
Description: two-times daily self-administration of nasal spray containing active substance (oxytocin) during five days after wounding.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two-times daily self-administration of nasal spray containing placebo during five days after wounding.
Study: NCT03718351

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transanal endoscopic microsurgery
Description: a TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic submucosal dissection
Description: an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
Study: NCT02643472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Navigator
Description: Parents will be contacted by the parent navigator within 2 business days after discharge to assess how the family is coping, answer questions, and provide necessary resources. Navigators will be in touch with families monthly and according to the parent's needs. They will assist the parent in making and keeping appointments, answer questions about insurance coverage, medical equipment and supplies, and serve as a liaison between parent and healthcare providers. However, the specific PN intervention for each family will be based on each family's needs and therefore may differ.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Care Notebook
Description: A care notebook will be provided to all parents at discharge. The notebook was created to provide resources and serve as an organizer for appointments for parents of NICU graduates. It was based on peer to peer feedback from former NICU parents, in addition, to community resources developed by current Parent Navigator Program at Children's National Health System.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Notebook
Description: A care notebook will be provided to all parents at discharge. The notebook was created to provide resources and serve as an organizer for appointments for parents of NICU graduates. It was based on peer to peer feedback from former NICU parents, in addition, to community resources developed by current Parent Navigator Program at Children's National Health System.
Study: NCT03448770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG- 17 gm sachet
Description: PEG- 17 gm sachet 3-4 times per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose : 20-30gm
Description: Lactulose : 20-30gm
Study: NCT03750786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arfolitixorin
Description: Bevacizumab 5 mg/kg intravenous infusion; Oxaliplatin 85 mg/m2 intravenous infusion; 5-FU 400 mg/m2 intravenous bolus; Arfolitixorin 60 mg/m2 intravenous bolus; 5-FU 2400 mg/m2 intravenous infusion; Arfolitixorin 60 mg/m2 intravenous bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Bevacizumab 5 mg/kg intravenous infusion; Oxaliplatin 85 mg/m2 intravenous infusion; Leucovorin 400 mg/m2 intravenous infusion; 5-FU 400 mg/m2 intravenous infusion; 5-FU 2400 mg/m2 intravenous infusion
Study: NCT04198064

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bag Squeeze
Description: Participants will receive a bag squeeze of irrigation fluid (500 ml/\~2 cups of % 0.9 saline solution) during the insertion of the cystocopy tube during their cystocopy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: No Bag Squeeze
Description: Participants will receive a standard cystocopy procedure as per standard of care.
Study: NCT01120730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluid resuscitation
Description: fluid resuscitation with HES

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluid resuscitation
Description: Fluid resuscitation in standardized fashion
Study: NCT02928159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mecta spectrum 5000Q device
Description: LAP-ST and Right Unilateral (RUL) electrode placement.
Study: NCT02905448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fat plant-based nutrition
Description: Conventional low fat plant-based meals free from animal source foods three times daily.~Plant-based meal replacement with Herbalife European Free From Vanilla formula two times daily.~Herbal beverage two times daily. Dietary fiber supplements is taken three times daily (10-36w) and more high fat whole plant-based foods (avocado, tofu, seeds) Conventional food intake is taken ad libitum and no calorie counts or restrictions will be applied.~From 10 to 36 weeks we added vitamin B12 and EPA+DHA fatty acid
Study: NCT04374214

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete Pulpotomy using Mineral Trioxide Aggregate
Description: Inflammed coronal pulp tissue will be removed till the canal orifices and mineral trioxide aggregate placed over the amputated pulp stump.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete Pulpotomy using Simvastain -alphatricalcium phosphate
Description: Inflammed coronal pulp tissue will be removed till the canal orifices and Simvastatin -alpha tricalcium phosphate placed over the amputated pulp stump.